Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Corvus Pharmaceuticals' Share-based Compensation rose 7016.35% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 6526.77%. This contributed to the annual value of $3.0 million for FY2024, which is 3986.96% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Share-based Compensation stood at $1.2 million, which was up 7016.35% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Share-based Compensation peaked at $1.3 million during Q2 2025, and registered a low of $492000.0 during Q1 2023.
  • Moreover, its 4-year median value for Share-based Compensation was $689000.0 (2024), whereas its average is $773266.7.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Share-based Compensation tumbled by 3342.35% in 2023, and later soared by 8156.75% in 2025.
  • Corvus Pharmaceuticals' Share-based Compensation (Quarter) stood at $620000.0 in 2022, then fell by 7.74% to $572000.0 in 2023, then surged by 41.96% to $812000.0 in 2024, then surged by 53.82% to $1.2 million in 2025.
  • Its Share-based Compensation stands at $1.2 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.3 million for Q1 2025.